Sodium Oxybate Will Have More Than 15 Percent of 2018 Fibromyalgia Market

Decision Resources … finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB’s sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Earth Times